Skip to content
RKWD
ROCKWOOD RESEARCH · A CORPORATE FILINGS WEBSITE|STRAIGHT FROM THE SOURCE · SEC EDGAR|SPONSOREDYour message on this tape — bid on the Rockwood Ad Exchange · Rockwood Ad Exchange|
Rockwood Research
…

ACRS

Aclaris Therapeutics, Inc.

Pharmaceutical Preparations · SIC 2834CIK 1557746Held by 5 tracked managersEDGAR filings ↗10-K/10-Q ↗

SHARE:XLINKEDINEMAIL
Revenue FY2025
$8.0M
Net Income FY2025
$(65.0M)
EPS (Basic, as reported)
$-0.53
Net Margin FY2025
-829.6%
ROE FY2025
-63.0%
Total Equity
$103.0M
Shares Out
147M
Business description

Aclaris Therapeutics, Inc. — Pharmaceutical Preparations. Figures are as reported in each year's original 10-K via SEC EDGAR XBRL company facts (FY2013–FY2025; structured XBRL data begins around 2008). Market-price metrics are not part of EDGAR data.

Annual (fiscal years, as reported)USD millions
i
default rows · click any row to chart itRevenue: 2 → 8 +18.9% CAGR
Fiscal yearFY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024⚑FY2025
Revenue—2104673031198
Cost of revenue—(1)(7)(4)(5)(5)(4)(3)(3)(2)
Gross profit—03———————
Research & development(33)(40)(63)(65)(32)(44)(78)(98)(34)(53)
Selling & marketing(3)00(1)——————
General & administrative(15)(33)(28)(27)(21)(24)(25)(32)(22)(22)
Total operating expenses(49)(73)(139)(115)(57)(96)(120)(129)(161)(84)
Operating income(49)(72)(135)(111)(51)(90)(90)(97)(142)(76)
Interest & investment income———————988
Other income (expense), net023(2)0(1)391011
Pre-tax income(48)(70)(133)(161)(51)(91)(87)(89)(132)(65)
Income tax expense—(2)——0——0——
Net income(48)(69)(133)(161)(51)(91)(87)(88)(132)(65)
EPS — basic———($3.90)($1.20)($1.60)($1.33)($1.27)($1.71)($0.53)
EPS — diluted———($3.90)($1.20)($1.60)($1.33)($1.27)($1.71)($0.53)
Shares outstanding — basic (M)———414357657077123
Shares outstanding — diluted (M)———414357657077123

Showing the latest 10 of 13 fiscal years.

  • ⚑ Weighted-average shares changed ×1.60 between FY2024 and FY2025 — a large issuance or reduction. Per-share figures on either side are as reported and not adjusted.

Source: SEC EDGAR XBRL company facts — figures as reported in each period's original filing (structured data begins ~2008). EPS and other per-share figures are as reported and are not adjusted for later stock splits; a ⚑ marks a period where the reported share count changed by a large factor. Dollar figures in millions unless per-share. Line items a company never reports are omitted. Where a filer switched XBRL concepts, the successor concept is used and definitions can differ slightly (e.g. cash may include restricted cash; banks' revenue is net of interest expense; cost of revenue may exclude D&A; net income may be the amount available to common stockholders; debt issued/repaid may be net of issuance costs or include finance-lease obligations — each only where the original concept stopped being reported). Click a period header to open that period's source filing on EDGAR.